ClinicalTrials.gg
TerminatedNCT01477853Updated Jul 26, 2018Results posted

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

A Phase 3 interventional study of Sitagliptin and Atorvastatin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-07-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early by the Sponsor for business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
81st of 197
166 · median 102
Started
2011
with 12 others
Phase 3
74 of 198
none open now
Registered
110th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 81st largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 110th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin alone and sitagliptin alone, respectively. Following a single-blind placebo run-in period, participants were to be randomized to one of three treatment arms (sitagliptin monotherapy, atorvastatin monotherapy, or sitagliptin plus atorvastatin) for 16 weeks (Phase A). During Phase B of the study (Weeks 16 through 54), participants were to receive either sitagliptin plus atorvastatin or glimepiride plus atorvastatin. The primary hypotheses were that after 16 weeks of treatment, sitagliptin in combination with atorvastatin reduces A1C from baseline more than atorvastatin alone, and that atorvastatin in combination with sitagliptin lowers LDL-C from baseline more than sitagliptin alone.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has type 2 diabetes mellitus
  • is a male, or a female who is highly unlikely to conceive
  • is currently on monotherapy with metformin (at least 1500 mg/day) for at least 8 weeks
  • is not on statin therapy or other lipid-lowering agents for at least 6 weeks

Exclusion criteria

Exclusion Criteria:

  • has a history of type 1 diabetes mellitus, ketoacidosis or possibly has type 1 diabetes
  • has ever taken a dipeptidyl peptidase IV inhibitor (such as sitagliptin, vildagliptin, alogliptin, or saxagliptin) or a glucagon-like peptide-1 mimetic (such as exenatide or liraglutide), or has required insulin therapy within 12 weeks prior to signing
  • has been on a peroxisome proliferator-activated receptor gamma agonist within the prior 12 weeks
  • has been treated with a statin or other lipid-lowering agents, including over the counter supplements of fish oils within 6 weeks
  • intends to consume at least 1.2 liters of grapefruit juice per day during the course of the study
  • is on or is likely to require treatment with 14 consecutive days or more, or repeated courses of
  • is on a weight loss program and not in the maintenance phase or has started a weight loss medication (such as orlistat or sibutramine) within the prior 8 weeks
  • has undergone a surgical procedure within the prior 4 weeks
  • has a history of myopathy or rhabdomyolysis with any statin.
  • has cardiovascular disease
  • has (NYHA) Class III or IV congestive heart failure, inadequately controlled hypertension, a medical history of active liver disease, chronic progressive neuromuscular disorder, is (HIV) positive, has a hematological disorder, uncontrolled endocrine or metabolic disease known to influence glycemic control or serum lipids/lipoproteins, untreated hyperthyroidism or is currently under treatment for hyperthyroidism
  • has a history of within 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • is pregnant or breastfeeding, or is intending to become pregnant or donate eggs within the projected duration of the study and post-study follow-up period
  • uses recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or increased alcohol consumption
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Sitagliptin/Sitagliptin + Atorvastatin

    In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.

    Drug: Sitagliptin · Drug: Atorvastatin · Other: Placebo to atorvastatin · Drug: Metformin (open-label) · Drug: Glimepiride (open-label) · Drug: Placebo to glimepiride

  • Active comparator
    Atorvastatin/Atorvastatin + Glimepiride

    In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.

    Drug: Atorvastatin · Other: Placebo to sitagliptin · Drug: Metformin (open-label) · Drug: Glimepiride (double-blind)

  • Experimental
    Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin

    In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.

    Drug: Sitagliptin · Drug: Atorvastatin · Drug: Metformin (open-label) · Drug: Glimepiride (open-label) · Drug: Placebo to glimepiride

Interventions

  • Sitagliptin 100 mg tablet orally daily

    Also known as: Januvia

  • Atorvastatin 80 mg tablet orally daily

    Also known as: Lipitor

  • OtherPlacebo to sitagliptin

    Placebo to sitagliptin tablet orally daily

  • OtherPlacebo to atorvastatin

    Placebo to atorvastatin tablet orally daily.

  • Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.

    Also known as: Glucophage

  • Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.

    Also known as: Amaryl

  • Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.

  • DrugPlacebo to glimepiride

    Phase B: placebo to glimepiride tablet orally daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 16

    A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 16

  2. Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

  3. Number of Participants Who Experienced at Least One Adverse Event

    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.

    Time frame: Up to 56 weeks (including 2-week follow-up)

  4. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.

    Time frame: Up to 54 weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16

    Change from baseline reflects the Week 16 value minus the Week 0 value.

    Time frame: Baseline and Week 16

  2. Percent Change From Baseline in Total Cholesterol at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

  3. Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

  4. Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

  5. Percent Change From Baseline in Triglycerides at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

  6. Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

  7. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16

    Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

    Time frame: Baseline and Week 16

07

Results

Posted Oct 5, 2016
Limitations and caveats
The study was terminated early by the Sponsor for business reasons. Due to the small number of participants included in the FAS, the results for Phase A and for the overall study should be interpreted with caution.

Participant flow

Note: 10 participants were enrolled in the study more than once (at more than 1 study site). Nine participants were enrolled twice and one participant was randomized at 3 different sites. Therefore, data of 10 actual participants (counted as 21 participants due to multiple screening/randomization) were removed from the efficacy analyses.

Phase A
Participant flow — Phase A
MilestoneSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Started555655
Completed121111
Not completed434544
Withdrew: Adverse event122
Withdrew: Lost to follow-up432
Withdrew: Physician decision101
Withdrew: Study terminated by sponsor374039
Phase B
Participant flow — Phase B
MilestoneSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Started121111
Completed000
Not completed121111
Withdrew: Lost to follow-up010
Withdrew: Study terminated by sponsor121011

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 16

A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent
Change From Baseline in Hemoglobin A1C (A1C) at Week 16
PercentSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Change From Baseline in Hemoglobin A1C (A1C) at Week 16-1.17 ± 0.200.04 ± 0.31-1.01 ± 0.22
PrimaryPercent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 164.9 ± 10.4-35.7 ± 7.1-38.7 ± 6.6
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 16

Change from baseline reflects the Week 16 value minus the Week 0 value.

Time frame:
Baseline and Week 16
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16
mg/dLSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16-15.7 ± 6.422.7 ± 10.1-26.0 ± 14.0
SecondaryPercent Change From Baseline in Total Cholesterol at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Total Cholesterol at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in Total Cholesterol at Week 16-1.7 ± 6.2-28.3 ± 4.8-25.7 ± 6.0
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16-4.8 ± 6.5-32.9 ± 5.6-29.0 ± 4.6
SecondaryPercent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16-1.0 ± 8.8-34.4 ± 6.7-34.6 ± 6.7
SecondaryPercent Change From Baseline in Triglycerides at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Triglycerides at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in Triglycerides at Week 16-9.9 ± 8.6-28.7 ± 6.5-10.5 ± 13.5
SecondaryPercent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16-15.5 ± 7.2-28.6 ± 6.6-10.4 ± 13.5
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16
Percent changeSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16-0.3 ± 3.2-5.8 ± 3.51.5 ± 6.0
PrimaryNumber of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.

Time frame:
Up to 56 weeks (including 2-week follow-up)
Reported as:
Number · Participants
Number of Participants Who Experienced at Least One Adverse Event
ParticipantsSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Number of Participants Who Experienced at Least One Adverse Event101313
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.

Time frame:
Up to 54 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Number of Participants Who Discontinued Study Drug Due to an Adverse Event122

Adverse events

Collected over Up to 56 weeks including 2-week follow-up (up to 56 weeks for serious adverse events, up to 54 weeks for non-serious adverse events). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin/Sitagliptin + Atorvastatin—0/55 (0%)3/55 (5.5%)
Atorvastatin/Atorvastatin + Glimepiride—0/56 (0%)3/56 (5.4%)
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin—1/55 (1.8%)5/55 (9.1%)
Most frequent serious events
Most frequent serious events
EventSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Inguinal herniaGastrointestinal disorders0/550/561/55
Most frequent other events
Most frequent other events
EventSitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + Atorvastatin
Glomerular filtration rate decreasedInvestigations1/550/563/55
Intentional overdoseInjury, poisoning and procedural complications2/553/562/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + AtorvastatinTotal
Mean56.2 ± 9.756.3 ± 8.253.7 ± 10.055.4 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin/Sitagliptin + AtorvastatinAtorvastatin/Atorvastatin + GlimepirideSitagliptin + Atorvastatin/Sitagliptin + AtorvastatinTotal
Female24272475
Male31293191
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Dec 2012, 13 months.

Results were first posted in Oct 2016, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2011
First posted
Nov 23, 2011
StartActual
Oct 24, 2011
Primary completionActual
Dec 4, 2012
CompletionActual
Dec 4, 2012
Results first posted
Oct 5, 2016
Last update
Jul 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01477853
Responsible party
Sponsor
First posted
Nov 23, 2011
Start date
Oct 24, 2011
Primary completion
Dec 4, 2012
Completion
Dec 4, 2012
Results posted
Oct 5, 2016
Last update
Jul 26, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion